Capella Biosciences

Name

Capella Biosciences

Website

https://capellabio.com

Company type

Private

Operating status

Closed

Short description

Capella Biosciences is a privately held pharmaceutical company headquartered in Palo Alto, United States, with Pek Lum as founder and CEO. Its web domain is currently parked and no operational products, pipeline, or business activity are documented.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Pharmaceutical development
• Drug discovery
• Therapeutics research
• Biopharmaceutical products
• Clinical development

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Core offering

Capella Biosciences is identified in the source data as a pharmaceutical company. No specific products, therapeutic areas, pipeline assets, or service offerings are disclosed; the company's website is a parked GoDaddy domain with no operational content.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Broad incumbents

• Amgen: Amgen is a global biotechnology and pharmaceutical company developing therapeutics across inflammation, oncology, and cardiometabolic disease. It is comparable to Capella as a broad incumbent pharma/biotech that competes for the same talent, capital, and licensing opportunities in the inflammation space where small biotechs typically operate.
• AbbVie: AbbVie is a major pharmaceutical company with a leading immunology franchise (Humira, Skyrizi, Rinvoq). It is comparable as a broad incumbent whose commercial success in inflammation defines the addressable market and partnership/licensing dynamics that small immunology biotechs like Capella would need to navigate.
• Genentech: Genentech, a member of the Roche Group, is a major Bay Area biotechnology company with deep inflammation and immunology R&D capabilities. It is comparable as a broad incumbent and a likely destination for talent, partnerships, and licensing deals that a small Palo Alto-based pharma would pursue.
• Regeneron Pharmaceuticals: Regeneron is a large biotechnology company with a strong inflammation and immunology R&D footprint and a track record of in-licensing or partnering early-stage assets. It is comparable as a broad incumbent that competes for the same scientific talent pool and partnership opportunities as a small inflammation-focused biotech.
• Vertex Pharmaceuticals: Vertex Pharmaceuticals is a Boston-area biotech that has expanded from its core franchise into adjacent therapeutic areas, including inflammation. It is comparable as a broad incumbent whose strategic expansion pattern illustrates the model a small pharma with limited disclosed pipeline could attempt to follow.
• Gilead Sciences: Gilead Sciences is a large biopharmaceutical company headquartered in the San Francisco Bay Area that acquires and partners with small biotechs to build its pipeline. It is comparable as a regional broad incumbent and a likely potential partner or acquirer for a small Palo Alto-based pharma company.

Direct peers

• Achaogen: Achaogen was a California-based antibiotic-focused biopharmaceutical company that ultimately filed for bankruptcy. It is directly comparable as a similarly positioned Bay Area small-cap pharma whose career path Pek Lum (Capella's founder) was previously associated with, illustrating the operational and capital risks facing small pharma companies.

Market position

Customer concentration

• Xx.com/capellabio

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Capella Biosciences